ArticleBMC women's health2026
Predictive value of serial dynamic lipid monitoring for pathologic complete response to neoadjuvant chemotherapy in luminal breast cancer: a retrospective study integrating metabolic and clinical indicators.
Article in BMC women's health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionNeoadjuvant chemotherapy (NAC) achieves a low pathological complete response (pCR) rate in Luminal breast cancer. Static lipid parameters have limited predictive value. This study evaluated the predictive role of dynamic cholesterol trajectory monitoring for pCR.
methodsThis retrospective study enrolled 201 patients with Luminal breast cancer who received NAC. Exclusion criteria comprised statin users and patients who discontinued treatment. Blood lipids were dynamically monitored at 8 time points following each chemotherapy cycle, and the linear slope (mg/dL/week) was calculated. pCR defined as ypT0/Tis ypN0, served as the primary endpoint. Multivariate logistic regression was employed to construct a predictive model that integrated lipid slope with key clinicopathological features. Internal validation was carried out using the bootstrap method with resampling. Model calibration and clinical usefulness were assessed using calibration curves and decision curve analysis (DCA). Furthermore, using gene set enrichment analysis and the Kaplan Meier plotter database, the association between hyperlipidemia related gene sets and breast cancer patient prognosis was validated in an external cohort.
resultA rising TC slope was inversely associated with pCR (non-pCR: 0.04 vs pCR: -0.01, p < 0.001). The standardized TC slope independently predicted pCR (HR = 0.40, 95% CI: 0.25-0.64, p < 0.001). A nomogram integrating TC slope, T stage, and HER2 status achieved an AUC of 0.816, outperforming clinical-only (AUC = 0.728) and lipid-only (AUC = 0.773) models (p < 0.05). High expression of hyperlipidemia-related genes correlated with poorer prognosis (p = 0.003). The calibration curve indicated good consistency between predicted and observed probabilities, and DCA demonstrated the model's clinical net benefit at threshold probabilities between 0.4 and 0.8.
conclusionDynamic TC trajectory is a novel metabolic biomarker predicting NAC response in Luminal breast cancer. Integration of dynamic lipid monitoring with clinical features may guide personalized treatment and early intervention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.